Achieving signalling selectivity of ligands for the corticotropin‐releasing factor type 1 receptor by modifying the agonist's signalling domain
- 1 July 2007
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 151 (6) , 851-859
- https://doi.org/10.1038/sj.bjp.0707293
Abstract
Background and purpose: Most of the pharmaceuticals target G‐protein‐coupled receptors (GPCRs) which can generally activate different signalling events. The aim of this study was to achieve functional selectivity of corticotropin‐releasing factor receptor type 1 (CRF1) ligands.Experimental approach: We systematically substituted urocortin, a natural peptide agonist of CRF1, with bulky amino acids (benzoyl‐phenylalanine, naphthylalanine) and determined the effect of the analogues on coupling of CRF1 to Gs‐ and Gi‐protein in human embryonic kidney cells, using receptor binding, [35S]‐GTPγS binding stimulation, and cAMP accumulation assays.Key results: Native ligands stimulated Gs and Gi activation through CRF1, resulting in stimulation and then inhibition of cAMP accumulation. Single replacements in urocortin at positions 6–15 led, dependent on the position and nature of the substituent, to ligands that conserved Gs activity, but were devoid of Gi activity, only stimulating cAMP accumulation, and competitively antagonized the Gi activation by sauvagine. In contrast, analogues with substitutions outside this sequence non‐selectively activated Gs and Gi, as urocortin did.Conclusions and implications: Modifications in a specific region, which we have called the signalling domain, in the polypeptide agonist urocortin resulted in analogues that behaved as agonists and, at the same time, antagonists for the activation of different G‐proteins by CRF1. This finding implies significant differences between active conformations of the receptor when coupled to different G‐proteins. A similar structural encoding of signalling information in other polypeptide hormone receptor ligands would result in a general concept for the development of signalling‐selective drug candidates.British Journal of Pharmacology (2007) 151, 851–859; doi:10.1038/sj.bjp.0707293Keywords
This publication has 22 references indexed in Scilit:
- Functional Selectivity and Classical Concepts of Quantitative PharmacologyThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Evidence that corticotropin‐releasing factor receptor type 1 couples to Gs‐ and Gi‐proteins through different conformations of its J‐domainBritish Journal of Pharmacology, 2006
- Regulation of the Coupling to Different G Proteins of Rat Corticotropin-releasing Factor Receptor Type 1 in Human Embryonic Kidney 293 CellsPublished by Elsevier ,2004
- G-Protein-Coupled Receptors: New Approaches to Maximise the Impact of GPCRs in Drug DiscoveryEmerging Therapeutic Targets, 2004
- Ligand-selective receptor conformations revisited: the promise and the problemTrends in Pharmacological Sciences, 2003
- The Extracellular N Terminus of the Endothelin B (ETB) Receptor Is Cleaved by a Metalloprotease in an Agonist-dependent ProcessJournal of Biological Chemistry, 2002
- N-terminal truncation of salmon calcitonin leads to calcitonin antagonists: Structure activity relationship of N-terminally truncated salmon calcitonin fragments in vitro and in vivoBiochemical and Biophysical Research Communications, 1992
- Alanine series of ovine corticotropin releasing factor (oCRF): a structure-activity relationship studyJournal of Medicinal Chemistry, 1992
- Structure-activity studies on the N-terminal region of growth hormone releasing factorJournal of Medicinal Chemistry, 1985
- Synthetic Competitive Antagonists of Corticotropin-Releasing Factor: Effect on ACTH Secretion in the RatScience, 1984